Recruiting
Phase 3

Hydrocortisone

Sponsor:

Jerry Zimmerman

Code:

NCT03401398

Conditions

Septic Shock

Eligibility Criteria

Sex: All

Age: 0 - 17

Healthy Volunteers: Not accepted

Interventions

Hydrocortisone, sodium succinate

Normal saline

Study Details

Brief summary:

SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock.

It is hypothesized that adjunctive hydrocortisone will significantly reduce the incidence of new and progressive organ dysfunction (primary outcome) and proportion of children with poor outcomes, defined as death or severely impaired health-related quality of life (HRQL) (secondary outcome), as assessed at 28 days following study enrollment (randomization).

Conditions

Septic Shock

Study ID

NCT03401398

Start date

Mar 11, 2019

Status verified date

May, 2025

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Sep 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 17

Healthy Volunteers: Not accepted

Inclusion Criteria:

A child receiving treatment in a pediatric intensive care unit is eligible for recruitment into SHIPSS if she/he meets all of the following inclusion criteria:

1. Age is at least 1 month (with corrected gestational age ≥42 weeks), but less than 17 years and 8 months of age
2. A documented focus of infection or a strong suspicion of infection at PICU admission, or for patients who develop septic shock during PICU stay, at the onset of the septic shock event
3. Surveillance cultures (e.g. blood, urine, cerebral spinal fluid, wound) and/or other microbial diagnostic tests have been obtained
4. One or more antimicrobials have been prescribed
5. Core temperature >38.5 C or <36.0 C or leukocytosis or leukopenia (as defined by the local laboratory) or a left-shifted leukocyte differential (>10% immature granulocyte forms) or a neutrophil count of <0.5 x 109 cells per litre documented at least once within the 24 hours preceding screening
6. Treatment with a continuous infusion of vasoactive-inotropic agent(s) to maintain mean or systolic arterial blood pressure above the age-appropriate target set by the treating clinician
7. Administration of two or more vasoactive-inotropic agents at any dose or epinephrine or norepinephrine infusion(s) alone at greater than or equal to 0.10 mcg/kg/min for >1 hour.

Exclusion Criteria:

A child receiving treatment in a pediatric intensive care unit for sepsis is ineligible for enrollment into SHIPSS if she/he meets any of the following exclusion criteria:

1. All inclusion criteria have been present for > 12 hours
2. Attending physician expects to prescribe systemic corticosteroids for an indication other than septic shock
3. Patient has received any doses of systemic corticosteroids during treatment for sepsis
4. Enrolled concurrently in a competing interventional clinical trial (formal assessment to be conducted by SHIPSS Core Committee for each potential competing trial)
5. Etomidate or ketoconazole treatment within past 48 hours
6. Patient in whom steroids are contraindicated at time of screening (e.g. treatment for systemic fungal infection, cerebral malaria, strongyloides)
7. Known or suspected hypothalamic, pituitary or adrenal disease (including patient has received acute or chronic corticosteroid administration and the physician intends to provide corticosteroid for suspected adrenal suppression)
8. Attending physician, PICU care team, or legally recognized guardians not committed to full treatment and resuscitation at the time of screening
9. Patient documented to be pregnant
10. Previous enrollment in the SHIPSS study
11. Patient admitted directly to the PICU with a thermal burn who has been in the PICU for <72 hours prior to meeting SHIPSS inclusion criteria.
12. (U.S. sites only) Patient in the custody of US protective services
13. Patient being evaluated for brain death
14. Vasoactive-inotropic agents prescribed solely for an indication other than septic shock
15. Confirmed dengue fever

Study Design

Enrollment

500 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Treatment

Approximately half of the subjects randomized into SHIPSS will be randomized into the Treatment Group and will receive hydrocortisone sodium succinate according to a predetermined dosing schedule.

placebo comparator: Placebo

Approximately half of the subjects randomized into SHIPSS will be randomized into the Placebo Group and will receive equivalent study drug volumes of normal saline.

Interventions

Hydrocortisone, sodium succinate

Patients randomized to the hydrocortisone treatment arm will receive an initial bolus of 2 mg/kg IV hydrocortisone, followed by 1 mg/kg (maximum 50 mg) of hydrocortisone dosed every six hours for a maximum of seven days or until all vasoactive infusions have been discontinued for at least 12 hours, whichever comes first. When the hydrocortisone course is completed, the medication will be discontinued.

Normal saline

Patients randomized to the placebo treatment arm will receive an equivalent volume of normal saline, with the identical dosing schedule to the intervention (hydrocortisone) arm.

Primary outcome measure

  • New or progressive multiple organ dysfunction syndrome as assessed utilizing the Pediatric Logistic Organ Dysfunction (PELOD-2) instrument. [ Time Frame: 28 days following study enrollment ]

Central Contacts and Locations

Central contacts

Locations

University of Arizona Medical Centre

Recruiting

Tucson, Arizona, United States, 85724

Children's Hospital of Los Angeles

Recruiting

Los Angeles, California, United States, 90027

UCSF Benioff Children's Hospital - Oakland

Recruiting

Oakland, California, United States, 94609

Children's Hospital of Orange County

Recruiting

Orange, California, United States, 92868

UCSF Benioff Children's Hospital - San Francisco

Recruiting

San Francisco, California, United States, 94143

Contacts

Patrick McQuillen, MD

McQuillP@ucsf.edu

Matt Zinter, MD

Matt.Zinter@ucsf.edu

Nemours Children's Health

Recruiting

Wilmington, Delaware, United States, 19803

University of Chicago, Comer Children's Hospital

Recruiting

Chicago, Illinois, United States, 60637

The University of Illinois at Chicago/OSF Children's Hospital of Illinois

Recruiting

Peoria, Illinois, United States, 61603

University of Louisville, Norton Children's Hospital

Recruiting

Louisville, Kentucky, United States, 40202

Boston Children's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Saint Barnabas Medical Center

Recruiting

Livingston, New Jersey, United States, 07039

Cincinnati Children's Hospital Medical Center

Recruiting

Cincinnati, Ohio, United States, 45229

The Children's Hospital at Oklahoma University Medical Center

Recruiting

Oklahoma City, Oklahoma, United States, 73104

Penn State Milton S. Hershey Children's Hospital

Recruiting

Hershey, Pennsylvania, United States, 17033

Primary Children's Hospital

Recruiting

Salt Lake City, Utah, United States, 84108

Seattle Children's Hospital

Recruiting

Seattle, Washington, United States, 98105

University of Wisconsin Health/American Family Children's Hospital

Recruiting

Madison, Wisconsin, United States, 53792

Alberta Children's Hospital

Recruiting

Calgary, Alberta, Canada, T3B 6A8

IWK Health Centre

Recruiting

Halifax, Nova Scotia, Canada, B3K 6R8

McMaster Children's Hospital

Recruiting

Hamilton, Ontario, Canada, L8N 3Z5

London Health Sciences Centre

Recruiting

London, Ontario, Canada, N6A 5W9

Children's Hospital of Eastern Ontario

Recruiting

Ottawa, Ontario, Canada, K1H 8L1

Contacts

Centre hospitalier universitaire Sainte-Justine

Recruiting

Montreal, Quebec, Canada, H3T 1C5

Centre hospitalier de l'Université Laval

Recruiting

Québec, Quebec, Canada, G1V 4G2

More Information

Sponsor

Jerry Zimmerman

Last update posted

Oct 30, 2025

Last verified

May, 2025

Keywords

  • hydrocortisone
  • refractory septic shock
  • sepsis
  • new/progressive MODS
  • mortality
  • health-related quality of life
  • corticosteroid adverse events
  • sepsis biomarkers

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Jerry Zimmerman on 2025-10-30.